Allogene Therapeutics, Inc. (ALLO) Executive Compensation
Allogene Therapeutics, Inc. (ALLO) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ALLO
CIK: 1737287
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2017 12:00:00 AM
Lead Engagement PartnerIshpal Shahpuri
Audit LocationSan Mateo, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13D/A | 2026-09-30 | — | SCHEDULE 13D/A Filing | 0001999371-26-021654 | View SEC Doc Filr Page |
| 8-K | 2026-09-02 | 2026-08-31 | 8-K | 0001193125-26-379423 | View SEC Doc Filr Page |
| 4 | 2026-08-25 | 2026-08-21 | FORM 4 | 0001628280-26-058920 | View SEC Doc Filr Page |
| 144 | 2026-08-21 | — | 144 Filing | 0001737287-26-000023 | View SEC Doc Filr Page |
| EFFECT | 2026-08-20 | — | EFFECT Filing | 9999999995-26-002725 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001231919-26-000912 | View SEC Doc Filr Page |
| S-3 | 2026-08-12 | — | S-3 | 0001628280-26-056232 | View SEC Doc Filr Page |
| 10-Q | 2026-08-12 | 2026-06-30 | 10-Q | 0001628280-26-056213 | View SEC Doc Filr Page |
| 8-K | 2026-08-12 | 2026-08-12 | 8-K | 0001628280-26-056198 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-07 | — | SCHEDULE 13G/A Filing | 0001296549-26-000008 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000093751-26-000405 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-07-01 | FORM 4 | 0001851044-26-000005 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001221355-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001737287-26-000021 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001737287-26-000019 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001197020-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001700969-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001548072-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-06-23 | 2026-06-18 | FORM 4 | 0001764157-26-000004 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-18 | 8-K | 0001628280-26-044618 | View SEC Doc Filr Page |
| 424B5 | 2026-06-22 | — | 424B5 | 0001628280-26-044616 | View SEC Doc Filr Page |
| DEFA14A | 2026-05-28 | — | DEFA14A | 0001193125-26-245501 | View SEC Doc Filr Page |
| 8-K | 2026-05-28 | 2026-05-28 | 8-K | 0001193125-26-245484 | View SEC Doc Filr Page |
| DEFA14A | 2026-05-21 | — | DEFA14A | 0001628280-26-036992 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001104659-26-062730 | View SEC Doc Filr Page |